Tommy Andersson

Tommy Andersson


If you made any changes in Pure these will be visible here soon.

Personal profile


Our studies are focused on the revelation of WNT5A, a secreted glycoprotein. WNT5A belongs to the non-transforming class of WNTs, and upon binding to different receptors or co-receptor complexes (Frizzled, RYK, ROR1/2, LRP5/6 and CD146), it elicits non-canonical (β-catenin-independent) signaling. WNT5A act as both tumor promoter as well as tumor suppressor, depending on cell type. For example, in breast cancer loss of WNT5A protein is associated with poor survival. In contrast, WNT5A expression is associated with increased metastasis and reduced survival in melanoma patients.  Our laboratory focusses on how WNT5A expression is regulated in these cancers and deciphering the WNT5A signaling pathways governing cancer cell migration and invasion.
On therapeutic front, we have developed a hexapeptide, Foxy5 (an agonist of WNT5A) which is currently in Phase1 clinical trial for breast cancer, prostate cancer and colon carcinoma (NCT02020291). Another peptide, Box5 (a WNT5A derived antagonist) is currently in pre-clinical trials for malignant melanoma.

UKÄ subject classification

  • Cancer and Oncology


  • WNT5A
  • Melanoma
  • Breast Cancer


Dive into the research topics where Tommy Andersson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or